Bladder Cancer VL

Advances in Bladder Cancer Beyond Immunotherapy and Checkpoint Inhibitors - Evan Yu

Details
(Length of Discussion: 9 min) Evan Yu and Alicia Morgans have a diverse conversation highlighting the advances in the field of bladder cancer beyond IO and Checkpoint inhibition. They introduce a variety of therapy options being studied such as FGFR inhibition, antibody-drug conjugates, HER-2 and DNA repair. Biographies: Evan Yu, MD Alicia Morgans, MD Referenced in this discussion: Targeted Therap...

High Grade Non-Muscle Invasive Bladder Cancer and BCG Refractory Patient - Josh Meeks

Details
(Length of Discussion: 12 min) Alicia Morgans and Josh Meeks highlight ongoing trials in non-muscle invasive bladder cancer. Reviews of SWOG 1602 and 1605, highlight the great work being done in the search for treatment options for patients with this disease, the ultimate hope for patients is to retain their bladder and potentially be cancer-free. Biographies: Joshua J Meeks, MD, Ph.D., is an Assi...

Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials -Pedro Barata

Details
(Length of Discussion: 21 min) Petros Grivas and Pedro Barata discuss how a recent study they performed applies to the field of metastatic urothelial cancer regarding the use of checkpoint inhibitors in a patient population outside the context of the clinical trial and the main objectives, results, and conclusion of that study as well as implications for the field. Biographies: Pedro Barata, MD, M...

Update on Bladder Cancer, Current Trials and Treatments - Bishoy Faltas

Details
(Length of Presentation: 10 min) Alicia Morgans, MD and Bishoy Faltas, MD have an energetic conversation about the tremendous progress they have seen in the recent years in bladder cancer. Dr. Faltas takes us through some of the current research with IO therapy, specifically checkpoint inhibition; where they are currently used and where the clinical data may expand the use of these agents. He revi...

CARMENA in mRCC and Surgical Management Cases in Bladder Cancer from ASCO 2018 - Tom Keane

Details
(Length of Discussion: 30 min) Tom Keane, MBBCh, FRCSI, FACS provides a detailed overview of the CARMENA study, presented by Arnaud Mejean MD, Ph.D. at ASCO 2018. This Phase III randomized trial assessed the utility and timing of CNx in the treatment paradigm of mRCC comparing patients who were randomized to either CNx and sunitinib vs sunitinib alone without CNx. He discusses the clinical applica...

Updates in Advanced Urothelial Carcinoma - Highlights from ASCO 2018 - Petros Grivas

Details
(Length of Discussion: 23 min) Petros Grivas and Alicia Morgans talk post-ASCO 2018 about a number of studies and abstracts presented. The first they review is the ABACUS study presented by Thomas Powles, MD. This single arm, phase II study investigated two cycles of atezolizumab (1200mg every three weeks) prior to radical cystectomy among patients with T2-4N0M0 urothelial carcinoma. The second st...

FDA ALERT: Efficacy Issue Identified in Some Patients Taking Pembrolizumab or Atezolizumab as Monotherapy to Treat Advanced Urothelial Cancer - Petros Grivas

Details
(Length of Discussion: 16 min) Petros Grivas and Alicia Morgans discuss the late-breaking FDA Alert announcing the label changes for Pembrolizumab and Atezolizumab as Monotherapy to Treat Urothelial Cancer with Low Expression of PD-L1. Biographies: Petros Grivas MD, Ph.D. a medical oncologist at Seattle Cancer Care Alliance with expertise in genitourinary cancers such as bladder cancer, prostate c...

Long-term Efficacy with Atezolizumab an IO Update- Arjun Balar

Details
(Length of conversation: 14 minutes) Alicia Morgans and Arjun Balar converse on the long-term efficacy data of atezolizumab in the 1st line setting as well as the 2nd line setting from the single-arm phase 2 trial. Discussion evolves to the recent safety alerts by the FDA highlighting the two studies, Keynote 361 and IMvigor 130. They question the applicability to clinical practice and the challen...

Journey from Oncologist to Cancer Survivor and Patient Advocate - Burton Needles

Details
(Length of Discussion: 12 min) Medical oncologist, bladder cancer survivor, and author of Journey from Oncologist to Cancer Survivor and Patient Advocate in the Era of Precision Medicine, Burt Needles who was diagnosed with a rare form of bladder cancer, plasmacytoid variant in 2013, talks with Alicia Morgans about his unique perspective as a medical oncologist and clinician to a cancer survivor a...

Setting the Stage for the BCG Unresponsive Population - Interview with Ashish Kamat

Details
(Length of Discussion: 11 min) Ashish Kamat, MD, MPH and Alicia Morgans, MD discuss non-muscle invasive bladder cancer, where the field stands particularly for BCG refractory patients and the definition of the BCG unresponsive patient. Ashish overviews the efforts of the SUO-CTC Bladder Committee and important updates and trials in this disease state . Biographies: Ashish M. Kamat, MD Alicia Morga...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe